BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Benitec Biopharma Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026
$8.36+0.25 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $413.29M
- P/E (TTM)
- –
- Dividend yield
- –
Benitec Biopharma Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Licensing revenue [Member] | $2.00K | $1.00K | $1.00K | $55.00K | – | $0 | $61.00K | $0 | 100.0% | – |
| Service revenue [Member] | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.00K | 0.0% | – |
| Royalty revenue [Member] | $0 | $0 | $0 | $0 | $20.00K | $28.00K | $16.00K | $29.00K | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Benitec Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.